With the objective to eliminate poliomyelitis caused by wild-type viruses insight, WHO advises that babies receive at least one dose of trivalent inactivated poliovirus vaccination (IPV), with bivalent oral poliovirus vaccine (OPV) (types 1 and 3) replacing trivalent OPV. The development of IPV (inactive polio vaccine) based on attenuated Sabin type polioviruses is being driven by limited production capacity and increasing constraints on manufacturers’ use of wild-type viruses. Takeda is working on a Sabin-based IPV (sIPV) to supplement global capacity and supply.

In this experiment, Japanese newborns and toddlers received three doses of the sIPV as a combination vaccination with diphtheria-tetanus-acellular pertussis antigens (DTaP-sIPV) as a three-dose primary series or as a booster dose in infants and toddlers.


In either newborns or toddlers, all formulations were immunogenic and well-tolerated, with no safety issues. The generation of neutralizing antibodies against Sabin polioviruses was dose-dependent, with the only statistically significant differences being between low-dose, medium-dose, and high-dose sIPVs. Neutralizing antibodies against Sabin and wild-type polioviruses were shown to be highly correlated. There was no discernible influence of sIPV dosage on immune responses to DTaP components or the combination vaccine’s reactogenicity profile.